Arcutis Biotherapeutics
ARQT
134 hedge funds and large institutions have $357M invested in Arcutis Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 54 increasing their positions, 37 reducing their positions, and 18 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 37
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
1% less funds holding
Funds holding: 136 → 134 (-2)
7.91% less ownership
Funds ownership: 116.85% → 108.94% (-7.9%)
48% less capital invested
Capital invested by funds: $684M → $357M (-$327M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
82% less call options, than puts
Call options by funds: $688K | Put options by funds: $3.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$2.92M |
| 2 |
Millennium Management
New York
|
+$2.63M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$2.52M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$2.23M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.09M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.62M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.36M |
| 4 |
Axa
Paris,
France
|
-$4.28M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.21M |
ARQT Hedge Fund Activity: Q3 2023 in Review
134 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q3 2023, worth a combined $357M — down 48% from $684M a quarter earlier.
Fund positioning in ARQT was balanced in Q3 2023: 18 funds opened new positions, 18 closed out, 54 added to existing stakes and 37 trimmed.
The largest buyer was Sio Capital Management, adding an estimated $2.92M. The largest seller was Fidelity Investments, cutting an estimated $8.09M.
- 134 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q3 2023, down from 136 in Q2 2023.
- Funds reported $357M of Arcutis Biotherapeutics stock for Q3 2023, down 48% quarter-over-quarter.
- 18 funds opened new Arcutis Biotherapeutics positions in Q3 2023 and 18 closed out, a net change of 0 holders.
- The largest Arcutis Biotherapeutics buyer in Q3 2023 was Sio Capital Management, an estimated $2.92M added.
- The largest Arcutis Biotherapeutics seller in Q3 2023 was Fidelity Investments, an estimated $8.09M sold.
Based on aggregated 13F filings for Q3 2023.